Rising trend of Enterococcus species as pathogen, and its antimicrobial susceptibility pattern in western Gujarat
Abstract
INTRODUCTION: Infections by enterococci pose a unique challenge as their ability to grow in extreme environments and intrinsic resistance to cephalosporin, clindamycin, and multidrug resistance. Enterococcus faecalis and Enterococcus faecium cause infections ranging from urinary tract infections (UTI) to bacteremia.
METHODOLOGY: A retrospective study on urine and blood specimens was conducted over 11 months (February-December 2024) to assess the prevalence, age-gender distribution, species isolation, and vancomycin resistant enterococci (VRE) profile to aid treatment. A total of 4,549 urine and 4,070 blood samples were processed and identified by conventional bacteriological methods. The drug susceptibility was assessed based on the Clinical and Laboratory Standards Institute (CLSI) guidelines using the disc diffusion method. E. faecalis (94.05%) outnumbered E. faecium (5.94%).
RESULTS: Enterococci prevalence rose to 7.08% among positive samples compared to 4.1% in 2023 and 2.70% in 2022. Females had more prevalence (69.30%) than males (30.69%); and the 21-40 years age group was the most common. Both species were most resistant to ampicillin and ciprofloxacin. High level aminoglycosides (HLA) and vancomycin resistance were 54.55% and 15.15% in E. faecalis, and 66.67% and 33.33% in E. faecium, respectively. Nitrofurantoin (69.69% sensitive) and fosfomycin (78.79% sensitive) can be good options for E. faecalis while formulating broad spectrum therapy for UTI. VRE isolation was…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.